| Literature DB >> 30265179 |
Gorav Batra1,2, Anders Ahlsson3, Bertil Lindahl1,2, Lars Lindhagen1, Anders Wickbom3, Jonas Oldgren1,2.
Abstract
BACKGROUND: The aim was to determine the association between atrial fibrillation (AF) and outcome in patients undergoing coronary artery bypass grafting (CABG).Entities:
Keywords: Atrial fibrillation; cardiovascular disease; coronary artery bypass grafting
Mesh:
Year: 2018 PMID: 30265179 PMCID: PMC6452910 DOI: 10.1080/03009734.2018.1504148
Source DB: PubMed Journal: Ups J Med Sci ISSN: 0300-9734 Impact factor: 2.384
Figure 1.Study population.
Baseline table: patient characteristics, admission year, and clinical and in-hospital characteristics of coronary artery bypass graft surgery patients in relation to atrial fibrillation status.
| Variable | No AF | Preoperative AF | Postoperative AF | |
|---|---|---|---|---|
| Demographics | ||||
| Age, median (IQR), years | 66 (60–72) | 72 (67–77) | 70 (64–75) | <0.001 |
| Sex, women | 1,171 (19.3) | 141 (19.1) | 406 (17.7) | 0.27 |
| Smoking, | 1,031 (18.3) | 84 (12.2) | 302 (14.0) | <0.001 |
| BMI, median (IQR), | 27.1 (24.7–29.7) | 27.2 (24.6–30.1) | 27.0 (24.7–29.7) | 0.55 |
| Admission year | 0.009 | |||
| 2010 | 1,901 (31.3) | 202 (27.4) | 643 (28.1) | |
| 2011 | 1,762 (29.0) | 206 (28.0) | 660 (28.8) | |
| 2012 | 1,670 (27.5) | 223 (30.3) | 657 (28.7) | |
| 2013 | 747 (12.3) | 106 (14.4) | 330 (14.4) | |
| Comorbidities and presentation at admission | ||||
| Diabetes mellitus | 1,851 (30.4) | 285 (38.7) | 675 (29.5) | <0.001 |
| Hypertension | 4,128 (67.9) | 594 (80.6) | 1,697 (74.1) | <0.001 |
| Myocardial infarction | 3,595 (59.1) | 560 (76.0) | 1,421 (62.1) | <0.001 |
| Congestive heart failure | 974 (16.0) | 280 (38.0) | 406 (17.7) | <0.001 |
| Peripheral vascular disease | 264 (4.3) | 56 (7.6) | 110 (4.8) | <0.001 |
| Thromboembolism | 14 (0.2) | 3 (0.4) | 10 (0.4) | 0.26 |
| Ischemic / unknown stroke | 287 (4.7) | 60 (8.1) | 114 (5.0) | <0.001 |
| Transient ischemic attack | 115 (1.9) | 37 (5.0) | 69 (3.0) | <0.001 |
| Hemorrhagic stroke | 44 (0.7) | 4 (0.5) | 15 (0.7) | 0.83 |
| Any bleeding | 291 (4.8) | 63 (8.5) | 98 (4.3) | <0.001 |
| Renal failure | 125 (2.1) | 50 (6.8) | 56 (2.4) | <0.001 |
| Chronic obstructive pulmonary disease | 319 (5.2) | 62 (8.4) | 138 (6.0) | 0.002 |
| Cancer diagnosis within 3 years | 146 (2.4) | 33 (4.5) | 61 (2.7) | 0.004 |
| Previous PCI | 1,365 (22.5) | 184 (25.0) | 490 (21.4) | 0.13 |
| Previous CABG | 99 (1.6) | 21 (2.8) | 35 (1.5) | 0.04 |
| Hospital course and perioperative data | ||||
| Indication for CABG, | <0.001 | |||
| Stable coronary artery disease | 2,533 (42.8) | 232 (32.4) | 921 (41.0) | |
| Unstable angina / Acute MI | 3,389 (57.2) | 485 (67.6) | 1,326 (59.0) | |
| EuroSCORE I, median (IQR), | 4 (2–6) | 6 (4–8) | 5 (3–7) | <0.001 |
| Extracorporeal circulation | 6,014 (98.9) | 724 (98.2) | 2,256 (98.5) | 0.14 |
| Number of central anastomoses, | <0.001 | |||
| 0 | 413 (8.5) | 48 (8.4) | 96 (4.8) | |
| 1 | 2,153 (44.1) | 254 (44.4) | 876 (44.2) | |
| 2 | 2,163 (44.3) | 250 (43.7) | 938 (47.3) | |
| ≥3 | 149 (3.1) | 20 (3.5) | 74 (3.7) | |
| Number of peripheral anastomoses, | <0.001 | |||
| 0 | 250 (5.1) | 17 (3.0) | 33 (1.7) | |
| 1 | 149 (3.1) | 24 (4.2) | 59 (3.0) | |
| 2 | 919 (18.8) | 106 (18.5) | 372 (18.8) | |
| ≥3 | 3,560 (73.0) | 425 (74.3) | 1,520 (76.6) | |
| Internal mammary artery, left, | 4,352 (89.2) | 497 (86.9) | 1,834 (92.4) | <0.001 |
| Internal mammary artery, right, | 92 (1.9) | 6 (1.0) | 30 (1.5) | 0.24 |
| Vein graft, | 4,465 (91.5) | 525 (91.8) | 1,882 (94.9) | <0.001 |
| Radial artery graft, | 59 (1.2) | 15 (2.6) | 49 (2.5) | <0.001 |
| Postoperative bleeds, | 207 (3.4) | 31 (4.2) | 113 (4.9) | 0.005 |
| Postoperative stroke, | 48 (0.8) | 12 (1.6) | 35 (1.5) | 0.003 |
| Left ventricular ejection fraction <50%, | 1,466 (27.0) | 307 (44.7) | 609 (29.7) | <0.001 |
| Creatinine, median (IQR), µmol/L, | 87 (75–105) | 100 (83–129) | 93 (79–120) | <0.001 |
| CHA2DS2-VASc score at discharge | <0.001 | |||
| CHA2DS2-VASc score =0 | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| CHA2DS2-VASc score =1 | 638 (10.5) | 13 (1.8) | 113 (4.9) | |
| CHA2DS2-VASc score ≥2 | 5,442 (89.5) | 724 (98.2) | 2,177 (95.1) | |
| Discharge medication | ||||
| Aspirin | 5,539 (91.1) | 512 (69.5) | 1,958 (85.5) | <0.001 |
| P2Y12 inhibitors | 955 (15.7) | 61 (8.3) | 311 (13.6) | 0.52 |
| Oral anticoagulants | 278 (4.6) | 338 (45.9) | 417 (18.2) | <0.001 |
| ACEI/ARB | 4,158 (68.4) | 522 (70.8) | 1,558 (68.0) | <0.001 |
| Calcium channel blockers | 1,146 (18.8) | 158 (21.4) | 473 (20.7) | <0.001 |
| Diuretics | 2,155 (35.4) | 402 (54.5) | 1,075 (46.9) | <0.001 |
| Statins | 5,492 (90.3) | 617 (83.7) | 2,034 (88.8) | 0.54 |
| Digoxin | 37 (0.6) | 89 (12.1) | 44 (1.9) | <0.001 |
| β-blockers | 5,433 (89.4) | 629 (85.3) | 1,973 (86.2) | <0.001 |
| Sotalol | 39 (0.6) | 27 (3.7) | 229 (10.0) | <0.001 |
| Amiodarone | 127 (2.1) | 111 (15.1) | 417 (18.2) | <0.001 |
| Verapamil / diltiazem | 59 (1.0) | 16 (2.2) | 30 (1.3) | <0.001 |
Characteristics were reported using percentages for categorical variables, or with median and IQR for continuous variables (as noted).
ACEI = angiotensin-converting enzyme inhibitors; AF = atrial fibrillation; ARB = angiotensin II receptor blockers; BMI = body mass index; CABG = coronary artery bypass grafting; CHA2DS2-VASc = congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, prior stroke, transient ischemic attack or thromboembolism, vascular disease, age 65–74 years, female sex; IQR = interquartile range; PCI = percutaneous coronary intervention.
Figure 2.Event rate of all-cause mortality in relation to atrial fibrillation status.
Figure 3.Event rate of recurrent symptomatic atrial fibrillation in relation to atrial fibrillation status.
Figure 4.Event rates according to the number of events per 100 person-years. Unadjusted and adjusted hazard ratios with a 95% confidence interval in relation to atrial fibrillation status, with no atrial fibrillation as reference.